Drug Approval | July 24, 2025
Lupin receives USFDA approvals for Liraglutide and Glucagon injectable products
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
The basket acquired, comprises of 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
Subscribe To Our Newsletter & Stay Updated
